Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765894 | 0.76 | NQO1 (0.35) | NQO1CYP1A1CYP1A2CYP1B1HPGD | |
| SCHEMBL21871901 | 0.74 | NQO1 (0.33) | NQO1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2817980 | 0.73 | NQO1 (0.32) | NQO1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL3373368 | 0.72 | ALOX5 (0.32) | — | |
| SCHEMBL5658620 | 0.71 | ALDH1A1 (0.37) | NQO1CYP1A1CYP1A2CYP1B1HSD17B10 | |
| SCHEMBL12731449 | 0.71 | CYP1A2 (0.33) | NQO1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2426989 | 0.70 | CA1 (0.41) | NQO1 | |
| SCHEMBL420546 | 0.70 | L3MBTL1 (0.43) | HPGDHSD17B10 | |
| SCHEMBL2737291 | 0.70 | NOTUM (0.32) | NQO1 | |
| SCHEMBL8272925 | 0.70 | NQO1 (0.34) | NQO1CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106048-B2 | protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester | 4SC AG (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-7812041-B2 | Heterocyclic NF-κB inhibitors | 4SC AG (DE) | 2010-10-12 | — | — | US | disclosed |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7601745-B2 | Heterocyclic NF-kB inhibitors | 4SC AG (DE) | 2009-10-13 | — | — | US | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | 4SC AG (DE) | 2008-10-23 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-11-02 | — | — | US | disclosed |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-03-30 | — | — | US | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | HSP90AA1 4047/4885HSP90AB1 3000/4885NQO1 126/4885 |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKBIA, IKBKB, NFKB2 | HSP90AA1 3287/4885HSP90AB1 1255/4885NQO1 32/4885 |
| US-20060247253-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFRKB, NFKB2 | HSP90AA1 3507/4885HSP90AB1 2039/4885NQO1 114/4885 |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, NFKB2, NFRKB | HSP90AA1 1618/4885HSP90AB1 557/4885NQO1 520/4885 |
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | HSP90AA1 3389/4885HSP90AB1 2859/4885NQO1 1924/4885 |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | HSP90AA1 819/4885HSP90AB1 467/4885NQO1 661/4885 |
| US-20120022068-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKB2, NFKBIA, NFRKB | HSP90AA1 4047/4885HSP90AB1 3000/4885NQO1 126/4885 |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | NFKBIA, NFKB2, NFRKB | HSP90AA1 1786/4885HSP90AB1 593/4885NQO1 474/4885 |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, IKBKB, NFKB2 | HSP90AA1 3272/4885HSP90AB1 1263/4885NQO1 34/4885 |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFKB2, NFRKB | HSP90AA1 1548/4885HSP90AB1 532/4885NQO1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.